Posted by Michael Wonder on 23 Jul 2017
Sunovion’s Latuda (lurasidone hydrochloride) receives Health Canada approval to treat adolescents with schizophrenia
21 July 2017 - Health Canada has also accepted for review a supplemental new drug submission for Latuda for the treatment of bipolar depression in paediatric patients.
Sunovion Pharmaceuticals today announced that Health Canada approved the Supplemental new drug submission for Latuda (lurasidone hydrochloride) for the management of the manifestations of schizophrenia in adolescents aged 15 to 17 years.
Latuda is currently indicated in Canada for the management of the manifestations of schizophrenia and the acute management of depressive episodes associated with bipolar I disorder in adults.
